alexa Treatment of Non-Segmental Vitiligo with Narrowband UVB Phototherapy (311 Nm): Clinical Efficacy and Mechanisms of Action
ISSN: 2155-9554

Journal of Clinical & Experimental Dermatology Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Treatment of Non-Segmental Vitiligo with Narrowband UVB Phototherapy (311 Nm): Clinical Efficacy and Mechanisms of Action

Diana Proshutinskaia*, Vladimir Volnukhin and Oksana Katunina

Department of Dermatology, State Research Center for Dermatovenereology and Cosmetology, Ministry of Health of Russian Federation, 3 Korolenko street, bldg. 6, Moscow, 107076, Russia

*Corresponding Author:
Diana Proshutinskaia
Department of Dermatology
State Research Center for Dermatovenereology and Cosmetology
Ministry of Health of Russian Federation
3 Korolenko street, bldg. 6
Moscow, 107076, Russia
Tel: +7(985)2318903
Fax: +7 (499)7852016
E-mail: [email protected]

Received date: July 24, 2014; Accepted date: September 26, 2014; Published date: October 03, 2014

Citation: Proshutinskaia D, Volnukhin V, Katunina O (2014) Treatment of Non- Segmental Vitiligo with Narrowband UVB Phototherapy (311 Nm): Clinical Efficacy and Mechanisms of Action. J Clin Exp Dermatol Res 5:240 doi:10.4172/2155-9554.1000240

Copyright: © 2014 Proshutinskaia D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, whichpermits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Objective: To estimate efficacy of narrowband UVB phototherapy (311 nm) in non-segmental vitiligo and its effect on subpopulations of T-cells and dendritic cells in vitiligo lesions. Methods: 56 patients with progressive non-segmental vitiligo underwent narrowband UVB phototherapy (311 nm). 11 patients had biopsies before and after therapy from lesional (depigmentation area), marginal, and perilesional skin for immunohistochemical studies of CD4+, CD8+, CD1a+ and CD83+ cells in epidermis and derma. Results: Median number of UVB procedures per course was 71, median total radiation dose-91.8 J/cm2, median percent of repigmentation-49%. Repigmentation of >25% of the affected area was reached in 67.9% of patients and repigmentation of 76-100% in 19.6% . VIDA index decreased from 2 to 1 post-treatment (P<0.035). In a subgroup who underwent immunohistochemical studies median number of UVB procedures per course was 88, median total dose of radiation-140.2 J/cm2, and median percent of repigmentation-50%. Significant activation of T-cellular immune reactions was found in lesions before treatment. There was a statistically significant increase in CD8+ lymphocytes and CD1a+ dendritic cells in marginal and perilesional normally pigmented skin in epidermis. There was an increase in CD4+ and CD8+ lymphocytes and CD83+ dendritic cells in all three zones in derma. Normalization of CD8+ and CD1+ cells in epidermis of the affected skin was observed post-treatment. There was only partial reduction of CD4+, CD8+ and CD1+ cells in dermis. Conclusions: Narrowband UVB phototherapy (311 nm) is an effective method of treatment of nonsegmental vitiligo. T-lymphocytes and Langerhans cells play a critical immunoregulatory role in narrowband UVB phototherapy (311 nm)-induced immune suppression. Lack of full normalization of immunological parameters in the skin after treatment indicates a need for optimization of narrowband UVB phototherapy (311 nm): conduction of longer courses including 150-200 procedures, or combinations of this treatment with immunosuppressive drugs.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version